Coherus BioSciences, Inc. 8C5.F Stock
Coherus BioSciences, Inc. Price Chart
Coherus BioSciences, Inc. 8C5.F Financial and Trading Overview
Coherus BioSciences, Inc. stock price | 1.46 EUR |
Previous Close | 4.76 EUR |
Open | 4.85 EUR |
Bid | 4.85 EUR x 50000 |
Ask | 5 EUR x 50000 |
Day's Range | 4.85 - 4.85 EUR |
52 Week Range | 3.7 - 9.69 EUR |
Volume | 2K EUR |
Avg. Volume | 121 EUR |
Market Cap | 456.59M EUR |
Beta (5Y Monthly) | 0.942605 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.69 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 25.71 EUR |
8C5.F Valuation Measures
Enterprise Value | 734.8M EUR |
Trailing P/E | N/A |
Forward P/E | -11.279069 |
PEG Ratio (5 yr expected) | -3.22 |
Price/Sales (ttm) | 2.490094 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 4.007 |
Enterprise Value/EBITDA | -3.128 |
Trading Information
Coherus BioSciences, Inc. Stock Price History
Beta (5Y Monthly) | 0.942605 |
52-Week Change | -21.34% |
S&P500 52-Week Change | 20.43% |
52 Week High | 9.69 EUR |
52 Week Low | 3.7 EUR |
50-Day Moving Average | 5.74 EUR |
200-Day Moving Average | 6.58 EUR |
8C5.F Share Statistics
Avg. Volume (3 month) | 121 EUR |
Avg. Daily Volume (10-Days) | 514 EUR |
Shares Outstanding | 94.08M |
Float | 67.91M |
Short Ratio | N/A |
% Held by Insiders | 1.88% |
% Held by Institutions | 103.23% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -148.012% |
Operating Margin (ttm) | -130.23% |
Gross Margin | -51.036% |
EBITDA Margin | -128.11% |
Management Effectiveness
Return on Assets (ttm) | -29.97% |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | 183.36M EUR |
Revenue Per Share (ttm) | 2.35 EUR |
Quarterly Revenue Growth (yoy) | -46.00000000000000000000000000000000% |
Gross Profit (ttm) | -58399000 EUR |
EBITDA | -234919008 EUR |
Net Income Avi to Common (ttm) | -271399008 EUR |
Diluted EPS (ttm) | -3.19 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 128.09M EUR |
Total Cash Per Share (mrq) | 1.59 EUR |
Total Debt (mrq) | 479.86M EUR |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 2.56 |
Book Value Per Share (mrq) | -2.441 |
Cash Flow Statement
Operating Cash Flow (ttm) | -255811008 EUR |
Levered Free Cash Flow (ttm) | -149084624 EUR |
Profile of Coherus BioSciences, Inc.
Country | Germany |
State | CA |
City | Redwood City |
Address | 333 Twin Dolphin Drive |
ZIP | 94065 |
Phone | 650 649 3530 |
Website | https://www.coherus.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 307 |
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company provides UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; and CIMERLI, a biosimilar to Lucentis, a biosimilar product interchangeable with Lucentis for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization in the United States. It also offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; and Shanghai Junshi Biosciences Co., Ltd. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Q&A For Coherus BioSciences, Inc. Stock
What is a current 8C5.F stock price?
Coherus BioSciences, Inc. 8C5.F stock price today per share is 1.46 EUR.
How to purchase Coherus BioSciences, Inc. stock?
You can buy 8C5.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Coherus BioSciences, Inc.?
The stock symbol or ticker of Coherus BioSciences, Inc. is 8C5.F.
Which industry does the Coherus BioSciences, Inc. company belong to?
The Coherus BioSciences, Inc. industry is Biotechnology.
How many shares does Coherus BioSciences, Inc. have in circulation?
The max supply of Coherus BioSciences, Inc. shares is 116.4M.
What is Coherus BioSciences, Inc. Price to Earnings Ratio (PE Ratio)?
Coherus BioSciences, Inc. PE Ratio is now.
What was Coherus BioSciences, Inc. earnings per share over the trailing 12 months (TTM)?
Coherus BioSciences, Inc. EPS is -0.69 EUR over the trailing 12 months.
Which sector does the Coherus BioSciences, Inc. company belong to?
The Coherus BioSciences, Inc. sector is Healthcare.